# Acadia Healthcare Company, Inc.: overview

ACHC · Nasdaq · CIK 1520697 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/achc.md) · [Financials](/companies/achc/financials.md) · [Filings](/companies/achc/filings.md) · [Insiders](/companies/achc/insiders.md)

Latest reported revenue: [$828.8m](/filings/0001193125-26-192508.md) for Q1 FY2026, three months to 2026-03-31, from the 10-Q filed Apr 30, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-192508).

## Last eight quarters

| Line item | Unit | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [796](/filings/0000950170-25-103160.md) | [816](/filings/0001193125-25-267062.md) | [774 d](/filings/0001193125-26-078266.md) | [771](/filings/0001193125-26-192508.md) | [869](/filings/0000950170-25-103160.md) | [852](/filings/0001193125-25-267062.md) | [821 d](/filings/0001193125-26-078266.md) | [829](/filings/0001193125-26-192508.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [9.9%](/filings/0001193125-25-267062.md) | [8.4%](/filings/0001193125-25-267062.md) | [4.2% d](/filings/0001193125-25-267062.md) | [1.1%](/filings/0001193125-26-192508.md) | [3.5%](/filings/0001193125-26-192508.md) | [4.3%](/filings/0001193125-26-192508.md) | [(143.3%) d](/filings/0001193125-26-192508.md) | [0.5%](/filings/0001193125-26-192508.md) |
| Diluted EPS | $ per share | [0.85](/filings/0000950170-25-103160.md) | [0.74](/filings/0001193125-25-267062.md) | not reported | [0.09](/filings/0001193125-26-192508.md) | [0.33](/filings/0000950170-25-103160.md) | [0.40](/filings/0001193125-25-267062.md) | not reported | [0.05](/filings/0001193125-26-192508.md) |
| Free cash flow | $m | [16.9 d](/filings/0000950170-25-103160.md) | [(27.1) d](/filings/0001193125-25-267062.md) | [(86.8) d](/filings/0001193125-26-078266.md) | [(163)](/filings/0001193125-26-192508.md) | [(34.2) d](/filings/0000950170-25-103160.md) | [(63.0) d](/filings/0001193125-25-267062.md) | [(179) d](/filings/0001193125-26-078266.md) | [(15.0)](/filings/0001193125-26-192508.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,314](/filings/0000950170-24-022057.md) | [2,610](/filings/0000950170-25-029095.md) | [2,929](/filings/0001193125-26-078266.md) | [3,154](/filings/0001193125-26-078266.md) | [3,313](/filings/0001193125-26-078266.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [8.2%](/filings/0000950170-24-022057.md) | [10.5%](/filings/0000950170-25-029095.md) | [(0.7%)](/filings/0001193125-26-078266.md) | [8.1%](/filings/0001193125-26-078266.md) | [(33.3%)](/filings/0001193125-26-078266.md) |
| Diluted EPS | $ per share | [2.10](/filings/0000950170-24-022057.md) | [2.98](/filings/0000950170-25-029095.md) | [(0.24)](/filings/0001193125-26-078266.md) | [2.78](/filings/0001193125-26-078266.md) | [(12.16)](/filings/0001193125-26-078266.md) |
| Free cash flow | $m | [130](/filings/0000950170-24-022057.md) | [84.4](/filings/0000950170-25-029095.md) | [38.2](/filings/0001193125-26-078266.md) | [(561)](/filings/0001193125-26-078266.md) | [(440)](/filings/0001193125-26-078266.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/achc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $441.7m | 14,957,168 |  | Added +3,270,779 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $169.1m | 5,726,246 |  | Reduced −3,346,696 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $158.6m | 5,369,461 |  | Added +308,023 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $148.1m | 5,015,727 |  | Reduced −1,851,951 |
| [CARRONADE CAPITAL MANAGEMENT, LP](/funds/1866872.md) | 2026-06-30 | $140.6m | 4,762,635 |  | Added +2,425,399 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $133.9m | 4,534,269 |  | Added +43,202 |
| [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $133.5m | 4,520,000 |  | Unchanged |
| [DME Capital Management, LP](/funds/1489933.md) | 2026-06-30 | $130.0m | 4,400,641 |  | Reduced −117,740 |
| [FARALLON CAPITAL MANAGEMENT, L.L.C.](/funds/909661.md) | 2026-06-30 | $124.6m | 4,220,800 |  | Added +2,484,000 |
| [ABRAMS BISON INVESTMENTS, LLC](/funds/1317588.md) | 2026-06-30 | $123.0m | 4,165,000 |  | Reduced −215,000 |

## Recent filings

[All 1,288 filings](/companies/achc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-25 | 20:12 ET | [8-K](/filings/0001437749-26-031225.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-031225 |
| 2026-07-28 | 20:57 ET | [8-K](/filings/0001437749-26-024693.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-024693 |
| 2026-07-28 | 20:30 ET | [10-Q](/filings/0001193125-26-321076.md) | Quarterly report, period 2026-06-30 | 0001193125-26-321076 |
| 2026-05-18 | 21:15 ET | [8-K](/filings/0001193125-26-229138.md) | 8.01 Other events | 0001193125-26-229138 |
| 2026-05-06 | 21:02 ET | [8-K](/filings/0001193125-26-209324.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-209324 |
| 2026-04-30 | 22:02 ET | [10-Q](/filings/0001193125-26-192508.md) | Quarterly report, period 2026-03-31 | 0001193125-26-192508 |
| 2026-04-29 | 21:22 ET | [8-K](/filings/0001437749-26-013916.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-013916 |
| 2026-04-23 | 20:20 ET | [8-K](/filings/0001193125-26-173769.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-173769 |
| 2026-03-25 | 21:02 ET | [DEF 14A](/filings/0001140361-26-011130.md) | Proxy statement, period 2026-05-06 | 0001140361-26-011130 |
| 2026-03-12 | 20:30 ET | [8-K](/filings/0001193125-26-104272.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-104272 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-078266.md), filed Feb 27, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1520697
- Tickers: ACHC
- Exchange: Nasdaq
- SIC code: 8093 Services-Specialty Outpatient Facilities, NEC
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.